These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 10834421)
1. Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction. Janssen MM; Snoek FJ; Masurel N; Hoogma RP; Devillé WL; Popp-Snijders C; Heine RJ Diabetes Care; 2000 May; 23(5):629-33. PubMed ID: 10834421 [TBL] [Abstract][Full Text] [Related]
2. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Roach P; Trautmann M; Arora V; Sun B; Anderson JH Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421 [TBL] [Abstract][Full Text] [Related]
3. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Heller SR; Amiel SA; Mansell P Diabetes Care; 1999 Oct; 22(10):1607-11. PubMed ID: 10526722 [TBL] [Abstract][Full Text] [Related]
4. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G; Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747 [TBL] [Abstract][Full Text] [Related]
5. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567 [TBL] [Abstract][Full Text] [Related]
6. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428 [TBL] [Abstract][Full Text] [Related]
7. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Lalli C; Ciofetta M; Del Sindaco P; Torlone E; Pampanelli S; Compagnucci P; Cartechini MG; Bartocci L; Brunetti P; Bolli GB Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931 [TBL] [Abstract][Full Text] [Related]
8. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Melki V; Renard E; Lassmann-Vague V; Boivin S; Guerci B; Hanaire-Broutin H; Bringer J; Belicar P; Jeandidier N; Meyer L; Blin P; Augendre-Ferrante B; Tauber JP Diabetes Care; 1998 Jun; 21(6):977-82. PubMed ID: 9614617 [TBL] [Abstract][Full Text] [Related]
10. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501 [TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Holcombe JH; Zalani S; Arora VK; Mast CJ; Clin Ther; 2002 Apr; 24(4):629-38. PubMed ID: 12017407 [TBL] [Abstract][Full Text] [Related]
12. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen? Heller SR; Amiel SA; Evans ML; Kong MF; Macdonald IA; Peacey SR Diabetes Obes Metab; 2002 Mar; 4(2):106-12. PubMed ID: 11940107 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Vignati L; Anderson JH; Iversen PW Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449 [TBL] [Abstract][Full Text] [Related]
14. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Jacober SJ; Scism-Bacon JL; Zagar AJ Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752 [TBL] [Abstract][Full Text] [Related]
15. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Holleman F; Schmitt H; Rottiers R; Rees A; Symanowski S; Anderson JH Diabetes Care; 1997 Dec; 20(12):1827-32. PubMed ID: 9405901 [TBL] [Abstract][Full Text] [Related]
16. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Ahmed AB; Home PD Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967 [TBL] [Abstract][Full Text] [Related]
17. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Kinsley BT; Weinger K; Bajaj M; Levy CJ; Simonson DC; Quigley M; Cox DJ; Jacobson AM Diabetes Care; 1999 Jul; 22(7):1022-8. PubMed ID: 10388961 [TBL] [Abstract][Full Text] [Related]
18. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500 [TBL] [Abstract][Full Text] [Related]
19. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Ebeling P; Jansson PA; Smith U; Lalli C; Bolli GB; Koivisto VA Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455 [TBL] [Abstract][Full Text] [Related]
20. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]